United Therapeutics Corporation (UTHR) Gross Margin
- Gross margin · 12 months: Value 86.14%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 86.14% | Gross profit / revenue. Period ending 2026-06-30. $2.72B ÷ $3.15B × 100 ≈ 86.14% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 2.72B USD | Gross Profit |
| Revenue | 3.15B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 437.20M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $2.72B | $3.15B | $437.20M | 86.14% |
| 2026-03-31 | $2.74B | $3.17B | $425.30M | 86.58% |
| 2025-12-31 | $2.80B | $3.18B | $384.40M | 87.92% |
| 2025-09-30 | $2.77B | $3.13B | $356.90M | 88.59% |
| 2025-06-30 | $2.74B | $3.08B | $339.10M | 88.98% |
| 2025-03-31 | $2.66B | $2.99B | $329.30M | 89.00% |
| 2024-12-31 | $2.57B | $2.88B | $309.70M | 89.24% |
| 2024-09-30 | $2.45B | $2.76B | $304.80M | 88.94% |
| 2024-06-30 | $2.32B | $2.62B | $291.80M | 88.85% |
| 2024-03-31 | $2.22B | $2.50B | $278.10M | 88.87% |
| 2023-12-31 | $2.07B | $2.33B | $257.50M | 88.94% |
| 2023-09-30 | $1.96B | $2.20B | $245.30M | 88.87% |
| 2023-06-30 | $1.90B | $2.11B | $212.40M | 89.94% |
| 2023-03-31 | $1.80B | $1.98B | $178.00M | 91.02% |
| 2022-12-31 | $1.78B | $1.94B | $151.60M | 92.17% |
| 2022-09-30 | $1.72B | $1.86B | $127.40M | 92.61% |
| 2022-06-30 | $1.66B | $1.79B | $117.90M | 92.85% |
| 2022-03-31 | $1.63B | $1.77B | $125.40M | 92.34% |
| 2021-12-31 | $1.56B | $1.69B | $122.50M | 92.73% |
| 2021-09-30 | (m) | $1.66B | $122.70M | (m) |
| 2021-06-30 | (m) | $1.59B | $119.00M | (m) |
| 2021-03-31 | (m) | $1.51B | $107.70M | (m) |
| 2020-12-31 | (m) | $1.48B | $108.10M | (m) |
| 2020-09-30 | (m) | $1.41B | $102.10M | (m) |
| 2020-06-30 | (m) | $1.43B | $111.10M | (m) |
| 2020-03-31 | (m) | $1.44B | $111.90M | (m) |
| 2019-12-31 | $1.33B | $1.45B | $117.60M | 91.88% |
| 2019-09-30 | (m) | $1.52B | $120.70M | (m) |
| 2019-06-30 | (m) | $1.53B | $139.60M | (m) |
| 2019-03-31 | (m) | $1.60B | $174.60M | (m) |
| 2018-12-31 | $1.43B | $1.63B | $198.70M | 87.79% |
| 2018-09-30 | (m) | $1.71B | (m) | (m) |
| 2018-06-30 | (m) | $1.74B | (m) | (m) |
| 2018-03-31 | (m) | $1.74B | (m) | (m) |
| 2017-12-31 | $1.62B | $1.73B | (m) | 93.87% |
| 2017-09-30 | (m) | $1.67B | (m) | (m) |
| 2017-06-30 | (m) | $1.63B | (m) | (m) |
| 2017-03-31 | (m) | $1.60B | (m) | (m) |
| 2016-12-31 | $1.53B | $1.60B | (m) | 95.45% |
| 2016-09-30 | (m) | $1.59B | (m) | (m) |
| 2016-06-30 | (m) | $1.57B | (m) | (m) |
| 2016-03-31 | (m) | $1.51B | (m) | (m) |
| 2015-12-31 | $1.40B | $1.47B | (m) | 95.29% |
| 2015-09-30 | (m) | $1.41B | (m) | (m) |
| 2015-06-30 | (m) | $1.35B | (m) | (m) |
| 2015-03-31 | $1.21B | $1.33B | (m) | 90.85% |
| 2014-12-31 | $1.15B | $1.29B | (m) | 89.53% |
| 2014-09-30 | $1.07B | $1.23B | (m) | 87.04% |
| 2014-06-30 | $1.05B | $1.20B | (m) | 87.53% |
| 2014-03-31 | $1.02B | $1.16B | (m) | 87.51% |
| 2013-12-31 | $975.82M | $1.12B | (m) | 87.36% |
| 2013-09-30 | $931.06M | $1.07B | (m) | 86.87% |
| 2013-06-30 | $874.72M | $1.01B | (m) | 86.43% |
| 2013-03-31 | $821.75M | $957.00M | (m) | 85.87% |
| 2012-12-31 | $786.83M | $916.08M | (m) | 85.89% |
| 2012-09-30 | $753.04M | $867.44M | (m) | 86.81% |
| 2012-06-30 | $718.44M | $826.71M | (m) | 86.90% |
| 2012-03-31 | $688.62M | $784.88M | (m) | 87.74% |
| 2011-12-31 | $652.19M | $743.18M | (m) | 87.76% |
| 2011-09-30 | (m) | $722.63M | (m) | (m) |
| 2011-06-30 | (m) | $689.46M | (m) | (m) |
| 2011-03-31 | (m) | $640.57M | (m) | (m) |
| 2010-12-31 | (m) | $603.83M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $369.85M | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $281.50M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |